Literature DB >> 24317278

Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.

Kulwara Poolpol1, Dorothea Orth-Höller2, Cornelia Speth1, Peter F Zipfel3, Christine Skerka3, Santiago Rodriguez de Córdoba4, Jens Brockmeyer5, Martina Bielaszewska6, Reinhard Würzner7.   

Abstract

Shiga toxin 2 (Stx2) is believed to be a major virulence factor of enterohemorrhagic Escherichia coli (EHEC) contributing to hemolytic uremic syndrome (HUS). The complement system has recently been found to be involved in the pathogenesis of EHEC-associated HUS. Stx2 was shown to activate complement via the alternative pathway, to bind factor H (FH) at short consensus repeats (SCRs) 6-8 and 18-20 and to delay and reduce FH cofactor activity on the cell surface. We now show that complement factor H-related protein 1 (FHR-1) and factor H-like protein 1 (FHL-1), proteins of the FH protein family that show amino acid sequence and regulatory function similarities with FH, also bind to Stx2. The FHR-1 binding site for Stx2 was located at SCRs 3-5 and the binding capacity of FHR-1*A allotype was higher than that of FHR-1*B. FHR-1 and FHL-1 competed with FH for Stx2 binding, and in the case of FHR-1 this competition resulted in a reduction of FH cofactor activity. FHL-1 retained its cofactor activity in the fluid phase when bound to Stx2. In conclusion, multiple interactions of key complement inhibitors FH, FHR-1 and FHL-1 with Stx2 corroborate our hypothesis of a direct role of complement in EHEC-associated HUS.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Complement regulatory proteins; EHEC; FH; FHL-1; FHR-1; FI; Factor H; Factor H-like protein 1; Factor H-related protein 1; HUS; Hemolytic uremic syndrome; MCP; SCRs; Shiga toxin; Stx; TCC; aHUS; atypical HUS; enterohemorrhagic Escherichia coli; factor H; factor H-like protein 1; factor H-related protein 1; factor I; heat-inactivated Stx; hemolytic uremic syndrome; hi-Stx; membrane cofactor protein; short consensus repeats; terminal complement complex

Mesh:

Substances:

Year:  2013        PMID: 24317278     DOI: 10.1016/j.molimm.2013.11.009

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  21 in total

Review 1.  Complementopathies.

Authors:  Andrea C Baines; Robert A Brodsky
Journal:  Blood Rev       Date:  2017-02-06       Impact factor: 8.250

2.  CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).

Authors:  Caroline Caillaud; Ariane Zaloszyc; Christoph Licht; Valérie Pichault; Véronique Frémeaux-Bacchi; Michel Fischbach
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

3.  C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Luciana Meni Bataglia; Ismael Toledo; Laura Beaudoin; Caupolican Alvarado
Journal:  Pediatr Nephrol       Date:  2019-09-02       Impact factor: 3.714

Review 4.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

Review 5.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Authors:  Tilo Freiwald; Behdad Afzali
Journal:  Adv Immunol       Date:  2021-11-19       Impact factor: 3.543

6.  HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.

Authors:  Carla Galvez; Paola Krall; Alejandro Rojas; Jun Oh; Francisco Cano
Journal:  Pediatr Nephrol       Date:  2022-08-15       Impact factor: 3.651

Review 7.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

8.  Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea.

Authors:  Hae Il Cheong; Sang Kyung Jo; Sung Soo Yoon; Heeyeon Cho; Jin Seok Kim; Young Ok Kim; Ja Ryong Koo; Yong Park; Young Seo Park; Jae Il Shin; Kee Hwan Yoo; Doyeun Oh
Journal:  J Korean Med Sci       Date:  2016-10       Impact factor: 2.153

9.  Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak.

Authors:  Tammy M Brady; Cozumel Pruette; Lauren F Loeffler; Darcy Weidemann; John J Strouse; Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Exp Nephrol       Date:  2016-05-06

10.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.